Enzyme Replacement Therapy
"Enzyme Replacement Therapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Therapeutic replacement or supplementation of defective or missing enzymes to alleviate the effects of enzyme deficiency (e.g., GLUCOSYLCERAMIDASE replacement for GAUCHER DISEASE).
| Descriptor ID |
D056947
|
| MeSH Number(s) |
E02.319.353.500
|
| Concept/Terms |
Enzyme Replacement Therapy- Enzyme Replacement Therapy
- Enzyme Replacement Therapies
- Replacement Therapies, Enzyme
- Replacement Therapy, Enzyme
- Therapies, Enzyme Replacement
- Therapy, Enzyme Replacement
|
Below are MeSH descriptors whose meaning is more general than "Enzyme Replacement Therapy".
Below are MeSH descriptors whose meaning is more specific than "Enzyme Replacement Therapy".
This graph shows the total number of publications written about "Enzyme Replacement Therapy" by people in this website by year, and whether "Enzyme Replacement Therapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 1 | 0 | 1 |
| 2012 | 2 | 0 | 2 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 2 | 2 | 4 |
| 2016 | 1 | 1 | 2 |
| 2017 | 1 | 1 | 2 |
| 2018 | 3 | 0 | 3 |
| 2019 | 3 | 1 | 4 |
| 2020 | 1 | 1 | 2 |
| 2021 | 0 | 3 | 3 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
| 2026 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Enzyme Replacement Therapy" by people in Profiles.
-
TRPML1 agonists synergize with enzyme replacement therapy in fibroblasts from Pompe disease patients. J Transl Med. 2026 Jun 11; 24(1).
-
Pancreatic Enzyme Use Reduces Pancreatitis Frequency in Children With Acute Recurrent or Chronic Pancreatitis: A Report From INSPPIRE. Am J Gastroenterol. 2024 10 01; 119(10):2094-2102.
-
Severe CNS involvement in a subset of long-term treated children with infantile-onset Pompe disease. Mol Genet Metab. 2024 02; 141(2):108119.
-
Gastrointestinal Factors Associated With Hospitalization in Infants With Cystic Fibrosis: Results From the Baby Observational and Nutrition Study. J Pediatr Gastroenterol Nutr. 2021 09 01; 73(3):395-402.
-
Transforming the clinical outcome in CRIM-negative infantile Pompe disease identified via newborn screening: the benefits of early treatment with enzyme replacement therapy and immune tolerance induction. Genet Med. 2021 05; 23(5):845-855.
-
Glycogen accumulation in smooth muscle of a Pompe disease mouse model. J Smooth Muscle Res. 2021; 57(0):8-18.
-
Brain delivery and activity of a lysosomal enzyme using a blood-brain barrier transport vehicle in mice. Sci Transl Med. 2020 05 27; 12(545).
-
The long-term safety and efficacy of vestronidase alfa, rhGUS enzyme replacement therapy, in subjects with mucopolysaccharidosis VII. Mol Genet Metab. 2020 03; 129(3):219-227.
-
Pharmacologic properties of high-dose ambroxol in four patients with Gaucher disease and myoclonic epilepsy. J Med Genet. 2020 02; 57(2):124-131.
-
Post-transplant laronidase augmentation for children with Hurler syndrome: biochemical outcomes. Sci Rep. 2019 Oct 01; 9(1):14105.